Tumor Board Review : Guideline and Case Reviews in Oncology.
Title:
Tumor Board Review : Guideline and Case Reviews in Oncology.
Author:
Todd III, Robert F.
ISBN:
9781617052231
Personal Author:
Edition:
2nd ed.
Physical Description:
1 online resource (449 pages)
Contents:
Cover -- Title -- Copyright -- Contents -- Contributors -- Preface to the Second Edition -- Preface to the First Edition -- Share Tumor Board Review: Guideline and Case Reviews in Oncology, Second Edition -- Chapter 1: Head and Neck Cancer -- Epidemiology, Risk Factors, Natural History, and Pathology -- Staging -- Overview of Staging -- Site-Specific Staging for SCCHN -- Case Summaries -- Locoregionally Advanced Disease -- Evidence-Based Case Discussion -- Recurrent/Metastatic SCCHN -- Evidence-Based Case Discussion -- Summary -- Review Questions -- References -- Chapter 2: Thyroid Cancer -- Epidemiology, Risk Factors, Natural History, and Pathology -- Differentiated Thyroid Carcinoma -- Staging -- Case Summaries -- Early-Stage Papillary Thyroid Cancer: Stage I -- Evidence-Based Case Discussion -- Differentiated Follicular Thyroid Cancer: Late-Stage Follicular Thyroid Cancer -- Evidence-Based Case Discussion -- Medullary Thyroid Cancer -- Evidence-Based Case Discussion -- Anaplastic Thyroid Cancer -- Evidence-Based Case Discussion -- Review Questions -- References -- Chapter 3: Non-Small-Cell Lung Cancer -- Epidemiology, Risk Factors, Natural History, and Pathology -- Staging -- Case Summaries -- Early-Stage NSCLC -- Evidence-Based Case Discussion -- Surgery and Adjuvant Chemotherapy in Early-Stage NSCLC -- Regional (Stage III) NSCLC -- Evidence-Based Case Discussion -- Metastatic NSCLC, Case 1 -- Evidence-Based Case Discussion -- Metastatic NSCLC, Case 2 -- Evidence-Based Case Discussion -- Recurrent NSCLC -- Evidence-Based Case Discussion -- Review Questions -- References -- Chapter 4: Small Cell Lung Cancer -- Epidemiology, Risk Factors, Natural History, and Pathology -- Staging -- Case Summaries -- LS-SCLC: Combined Modality Therapy -- Evidence-Based Case Discussion -- ES-SCLC: Systemic Palliative Therapy -- Evidence-Based Case Discussion.
Review Questions -- References -- Chapter 5: Breast Cancer -- Epidemiology, Risk Factors, Natural History, and Pathology -- Staging -- Case Summaries -- Ductal Carcinoma In Situ -- Early-Stage ER+ Breast Cancer -- Early-Stage ER+ Breast Cancer, Stage I or II -- Early-Stage TNBC -- Locally Advanced HER2+ Breast Cancer -- Metastatic Breast Cancer -- A Special Note on Breast Cancer in Pregnancy -- Review Questions -- References -- Chapter 6: Esophageal Cancer -- Epidemiology, Risk Factors, Natural History, and Pathology -- Staging -- Case Summaries -- Locally Advanced Resectable Esophageal Cancer -- Evidence-Based Case Discussion -- Locally Advanced Unresectable Esophageal Cancer -- Evidence-Based Case Discussion -- Metastatic Esophageal Cancer -- Evidence-Based Case Discussion -- Acknowledgment -- Review Questions -- References -- Chapter 7: Gastric Cancer -- Epidemiology, Natural History, Risk Factors, and Pathology -- Staging -- Case Summaries -- Resectable Gastric Cancer -- Evidence-Based Case Discussion -- Locally Advanced Unresectable and Metastatic Gastric Cancer -- Evidence-Based Case Discussion -- Review Questions -- References -- Chapter 8: Pancreatic Cancer -- Epidemiology, Risk Factors, Natural History, and Pathology -- Staging -- Case Summaries -- Resectable Pancreatic Adenocarcinoma -- Evidence-Based Case Discussion -- Metastatic (Unresectable) Pancreatic Cancer -- Evidence-Based Case Discussion -- Metastatic Pancreatic Neuroendocrine (Islet) Carcinoma -- Evidence-Based Case Discussion -- Review Questions -- References -- Chapter 9: Neuroendocrine Cancer -- Epidemiology, Risk Factors, Natural History, and Pathology-General -- Well-Differentiated Neuroendocrine Tumors -- Epidemiology, Risk Factors, Natural History, and Pathology -- Staging -- Case Summary -- Well-Differentiated NETs -- Evidence-Based Case Discussion.
Pancreatic Neuroendocrine Tumors (Intermediate Grade) -- Epidemiology, Risk Factors, Natural History, and Pathology -- Staging -- Case Summary -- Pancreatic Neuroendocrine Tumors -- Evidence-Based Case Discussion -- Adrenocortical Carcinoma -- Epidemiology, Risk Factors, Natural History, and Pathology -- Staging -- Case Summary -- Metastatic ACC -- Evidence-Based Case Discussion -- Poorly Differentiated (High-Grade) Extrapulmonary Neuroendocrine Carcinomas -- Epidemiology, Risk Factors, Natural History, and Pathology -- Case Summary -- High-Grade/Poorly Differentiated NETs -- Evidence-Based Case Discussion -- Review Questions -- References -- Chapter 10: Hepatobiliary Cancers -- Biliary Tract Carcinomas -- Epidemiology, Risk Factors, Natural History, and Pathology -- Staging -- Case Summaries -- Locally Advanced/Unresectable BTC -- Evidence-Based Case Discussion -- Metastatic BTC -- Evidence-Based Case Discussion -- Hepatocellular Carcinoma -- Epidemiology, Risk Factors, Natural History, and Pathology -- Staging -- Case Summaries -- Locally Advanced HCC -- Evidence-Based Case Discussion -- Metastatic HCC -- Evidence-Based Case Discussion -- Review Questions -- References -- Chapter 11: Colorectal Cancer -- Epidemiology, Risk Factors, Natural History, and Pathology -- Case Summaries -- Unresectable Metastatic CRC -- Evidence-Based Case Discussion -- Vascular Endothelial Growth Factor Inhibitors -- Summary -- Potentially Resectable or Resectable Metastatic CRC -- Evidence-Based Case Discussion -- Stage III Colon Cancer: Adjuvant Chemotherapy -- Evidence-Based Case Discussion -- Summary -- Stage II Colon Cancer: Adjuvant Chemotherapy -- Evidence-Based Case Discussion -- Summary -- Rectal Cancer -- Evidence-Based Case Discussion -- Summary -- Review Questions -- References -- Chapter 12: Anal Cancer.
Epidemiology, Risk Factors, Natural History, and Pathology -- Staging -- Case Summaries -- Limited Stage Anal Carcinoma -- Metastatic Anal Carcinoma -- Future Directions -- Review Questions -- References -- Chapter 13: Prostate Cancer -- Epidemiology, Risk Factors, and Natural History -- Pathology and Staging -- Case Summaries -- Clinically Localized Prostate Cancer -- Evidence-Based Case Discussion -- PSA-Only (Biochemical) Recurrence -- Evidence-Based Case Discussion -- Metastatic Prostate Cancer -- Evidence-Based Case Discussion -- Review Questions -- References -- Chapter 14: Testicular Cancer -- Epidemiology, Risk Factors, Natural History, and Pathology -- Staging -- Case Summaries -- Early-Stage Seminoma -- Evidence-Based Case Discussion -- Early-Stage NSGCTs -- Evidence-Based Case Discussion -- Locally Advanced Seminoma -- Evidence-Based Case Discussion -- Locally Advanced NSGCTs -- Evidence-Based Case Discussion -- Intermediate Risk, Advanced NSGCTs -- Evidence-Based Case Discussion -- Poor-Risk, Advanced GCT With Extrapulmonary Metastases -- Evidence-Based Case Discussion -- Extragonadal NSGCTs -- Evidence-Based Case Discussion -- Developing Concepts in GCT Responsiveness to Conventional Therapy -- Review Questions -- References -- Chapter 15: Kidney Cancer -- Epidemiology, Risk Factors, Natural History, and Pathology -- Staging -- Case Summaries -- Limited-Stage RCC -- Evidence-Based Case Discussion -- Locally Advanced RCC -- Evidence-Based Case Discussion -- Advanced RCC -- Evidence-Based Case Discussion -- Review Questions -- References -- Chapter 16: Bladder Cancer -- Epidemiology, Risk Factors, Natural History, and Pathology -- Staging -- Case Summaries -- Non-Muscle-Invasive Tumors (Ta, Tis, T1) -- Evidence-Based Case Discussion -- Muscle-Invasive Disease (T2 or T3 or T4a) -- Evidence-Based Case Discussion.
Unresectable (T4b) or Metastatic Disease (N1-3 or M1) -- Evidence-Based Case Discussion -- Review Questions -- References -- Chapter 17: Cervical Cancer -- Epidemiology, Risk Factors, Natural History, and Pathology -- Staging -- Case Summaries -- Early-Stage Cervical Cancer -- Evidence-Based Case Discussion -- Locally Advanced Cervical Cancer -- Evidence-Based Case Discussion -- Distant Metastatic Cervical Cancer -- Evidence-Based Case Discussion -- Review Questions -- References -- Chapter 18: Uterine Cancer -- Epidemiology, Risk Factors, Natural History, and Pathology -- Case Summaries -- Early-Stage Endometrial Cancer -- Evidence-Based Case Discussion -- Locally Advanced Endometrial Cancer -- Evidence-Based Case Discussion -- Recurrent and Metastatic Endometrial Cancer -- Evidence-Based Case Discussion -- High-Risk Malignant GTD -- Evidence-Based Case Discussion -- Review Questions -- References -- Chapter 19: Ovarian Cancer -- Epidemiology, Risk Factors, Natural History, and Pathology -- Staging -- Case Summaries -- Early-Stage Disease -- Evidence-Based Case Discussion -- Advanced-Stage Disease -- Evidence-Based Case Discussion -- Recurrent Disease -- Evidence-Based Case Discussion -- Review Questions -- Acknowledgment -- References -- Chapter 20: Melanoma -- Epidemiology, Risk Factors, Natural History, and Pathology -- Staging -- Case Summaries -- Early-Stage Melanoma (Stage II or III) -- Evidence-Based Case Discussion -- Locoregional and Metastatic (Stage IV) Melanoma -- Evidence-Based Discussion -- Review Questions -- References -- Chapter 21: Bone Sarcoma -- Osteosarcoma -- Epidemiology, Risk Factors, Natural History, and Pathology -- Staging -- Case Summaries -- Early-Stage Osteosarcoma -- Evidence-Based Case Discussion -- Advanced-Stage Osteosarcoma -- Evidence-Based Case Discussion -- Ewing's Sarcoma.
Epidemiology, Risk Factors, Natural History, and Pathology.
Abstract:
p> Praise for the First Edition:. "As everyone in oncology fellowship training knows, there is a huge [information] gap in this field. Most oncology books are massive and loaded with information...by the time the book is [published]...it is outdated." [Tumor Board Review] is fresh and just out of the oven...I haven't seen any book in oncology like this so far...I think my investment in this book was wise and worth it." - Humaid Al-Shamsi, MB(Hon), BMedSc, MRCP(UK), FRCP, FACP, Assistant Professor, The University of Texas, MD Anderson Cancer Center. Culling the knowledge and expertise of respected oncology specialists, this is a concise yet comprehensive review of all areas of oncology practice for medical oncologists, radiation oncologists, and pathologists--both students and practitioners. The second edition of Tumor Board Review has been thoroughly revised to encompass recent scientific advances in assessment and treatment, new clinical guidelines, and new FDA-approved drugs and indications. It also contains approximately 350 multiple-choice questions and answers to assist readers in testing their knowledge, especially those preparing for the MOC exam. The book features case presentations and evidence-based management discussions that clearly demonstrate how to apply new information in daily practice. In a consistent format, each chapter addresses epidemiology, risk factors, natural history, and pathology of each major organ-specific tumor type; an abbreviated display of relevant staging; and several "tumor board style" illustrative patient case studies. This is followed by an evidence-based case discussion, which reinforces current guidelines and explains the rationale for the diagnostic and therapeutic steps taken. Algorithms and decision-tree graphics further illuminate the decision process. New to the Second Edition of Tumor Board Review
:.: Revised and updated with state-of-the-art knowledge; Presents the most recent guidelines and management standards in user-friendly format; Focuses on current indications, use of new drugs, and new treatment of side effects; Includes new FDA-approved drugs and guidelines; Offers approximately 350 multiple-choice questions and answers
Local Note:
Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2017. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries.
Genre:
Electronic Access:
Click to View